Presentation is loading. Please wait.

Presentation is loading. Please wait.

Monocytes from melanoma patients are unresponsive to TLR3 agonists.

Published byAgnes Arntzen Modified over 5 years ago

Similar presentations

Presentation on theme: "Monocytes from melanoma patients are unresponsive to TLR3 agonists."— Presentation transcript:

1 Monocytes from melanoma patients are unresponsive to TLR3 agonists.
Monocytes from melanoma patients are unresponsive to TLR3 agonists. Healthy volunteer leukocytes (A) and malignant melanoma patients' (MMP) leukocytes (B) stimulated with poly (I:C), dotted line and control, dashed line. Histogram of CD80 expression following 6-hour stimulation on monocytes (B). An increase in the expression of CD80 is not observed in patients with malignant melanoma following stimulation with poly (I:C). Representative histograms from a total of three independent experiments. Rahul Chavan et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Download ppt "Monocytes from melanoma patients are unresponsive to TLR3 agonists."

Similar presentations

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.
Glioma-derived soluble factor(s) enhance IL-10 signaling.

Glioma-derived soluble factor(s) enhance IL-10 signaling.
Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.

Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.
Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Melanoma donor (MD) NK cells are functionally impaired/exhausted.
CD25 expression is associated with unfavorable clinical outcome.

CD25 expression is associated with unfavorable clinical outcome.
Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.

Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Cetuximab treatment increases IFNγ receptor 1 expression.

Cetuximab treatment increases IFNγ receptor 1 expression.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
The absence of ADCC by nivolumab in vitro.

The absence of ADCC by nivolumab in vitro.
Comparison of cytokine profiles induced by ChiLob 7/4 and TLR ligands in ex vivo whole-blood stimulation assays. Comparison of cytokine profiles induced.

Comparison of cytokine profiles induced by ChiLob 7/4 and TLR ligands in ex vivo whole-blood stimulation assays. Comparison of cytokine profiles induced.
Quantification of MHC-I, β2m, and T-cell subsets.

Quantification of MHC-I, β2m, and T-cell subsets.
PD-1 blockade enhances T-cell function.

PD-1 blockade enhances T-cell function.
A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b and CD118. A and.

A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b and CD118. A and.
Exosome-mediated inhibition of T cells is reversible.

Exosome-mediated inhibition of T cells is reversible.
Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.

Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.

Similar presentations

Ads by Google